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Abstract
Hereditary myopathy with early respiratory failure is an autosomal dominant myopathy caused by mutations in the 119th
fibronectin-3 domain of titin. To date all reported patients with the most common mutation in this domain (p.C30071R) appear to
share ancestral disease alleles. We undertook this study of two families with the p.C30071R mutation to determine whether they
share the same haplotype as previously reported British families or whether the mutation arose as a de novo event. We sequenced the
119th fibronectin-3 domain in these two probands and flanking polymorphisms associated with the British haplotype in hereditary
myopathy with early respiratory failure. A family of Indian descent had a haplotype that was not compatible with the British shared
haplotype. Cloning of the 119th fibronectin-3 domain in this patient demonstrated polymorphisms rs191484894 and novel noncoding
variant c.90225C>T on the same allele as the mutation, which is distinct from previously reported British families. This proves that
the p.C30071R mutation itself (rather than the haplotype containing this mutation) causes hereditary myopathy with early
respiratory failure and suggests its independent origin in different ethnic groups.
Ó 2013 The Authors. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Hereditary myopathy with early respiratory failure
(HMERF) is an autosomal dominant myopathy causing
skeletal muscle weakness (proximal and/or distal) with
early involvement of respiratory muscles. It is caused by
mutations in the 119th fibronectin 3 (FN3) domain of
titin (TTN) [1,2]. The clinical presentation can be quite
variable, although the condition should be particularly
suspected in patients with disease onset in mid-life, with
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preferential involvement of distal leg muscles, and
symptoms of respiratory muscle weakness such as
orthopnoea [2]. Creatine kinase is often mildly elevated
(up to 1000 U/ml) and muscle MRI shows a
characteristic pattern which includes fatty infiltration of
semitendinosus, sartorius and gracilis at the thigh and
anterior compartment lower leg muscles [2]. The
condition meets diagnostic criteria for myofibrillar
myopathy on muscle pathology, and has been identified
in approximately 5% of undiagnosed myofibrillar
myopathy cohorts from two separate studies [3,4],
although muscle pathology may also be nonspecific in
some patients [2]. The first mutation to be associated
with HMERF was the p.R32450W mutation in the
kinase domain [5]. However, no further HMERF cases
with kinase domain mutations have since been identified
[3,6], and this variant is now reported as a low frequency
polymorphism in controls of European descent
(rs140319117), and patients from this family also have a
mutation in the 119th FN3 domain of TTN [7].
The most common mutation associated with this
condition is the p.C30071R mutation in TTN, present in
20 of 30 reported HMERF families [1–4,8,9]. However,
to date all families characterised with this mutation share
common haplotypes, implying that all have inherited an
ancestral allele: 8 UK-based families and one Canadian
family (with British ancestry) share a single haplotype
[3,9]. All families with this mutation reported by Palmio
and colleagues also share a common haplotype, which
includes a British family (Family E) [8], and three
previously reported Scandinavian families [1]. Given that
British families are involved in both studies, it is
probable that all families share the same haplotype,
although this is not confirmed given the different
methodologies employed in defining the haplotypes
between studies. This leaves only two non-UK families
with this mutation whose haplotypes have not been
characterised, from the work of Toro et al. [4]. We
studied these two families to determine whether the
p.C30071R mutation in these patients is on the same
ancestral allele, or whether it occurred as a de novo event.
2. Materials and methods
The probands of two previously reported families
(Family B and Family C from Toro et al. [4]) were
studied in this report. Family B resides in Canada
although is of Indian ancestry. Family C is of Spanish
descent. Neither of these families is known to have
British ancestors. Clinical details are described in the
Fig. 1. (A) The shared haplotypes are demonstrated, assuming the minimum number of recombinations. Green boxes indicate reference sequence, whereas
blue boxes indicate the polymorphic variant. The HMERF mutation is indicated by red boxes. The UK common haplotype represented here is the shared
haplotype in 5 of 8 reported UK families, although a black box in this column indicates the core haplotype of 171 kbp which is shared by all 8 families.
Family B (India) does not share the haplotype. The column for Family C (Spain) indicates the compatible shared haplotype with UK families (outlined by
a black box). (B) Sequencing chromatograph demonstrating the cloned disease allele from the 119th FN3 domain in Family B. The amber band indicates
the reference sequence. The upper trace is the region immediately surrounding the HMERF mutation c.90211T>C (p.C30071R) (indicated by a red
arrow). The novel noncoding variant c.90225C>T is on the same allele as the mutation and indicated by a black arrow. The lower trace is the sequence
immediately surrounding the other heterozygous variant, c.90374C>T (a.k.a: rs191484894) which also segregated with the disease mutation on the same
allele.
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work by Toro et al. [4]. Sequencing of leucocyte DNA was
performed using previously described methods for the
119th FN3 domain of TTN and flanking polymorphisms
that define the UK haplotype [3]. Haplotypes were
manually reconstructed assuming the minimum number
of recombinations. The PCR-amplified 119th FN3
domain from Family B was gel purified using Qiaquick
gel extraction kit (Qiagen, Manchester UK), ligated into
pGEM-T vector system (Promega, Southampton, UK),
heat-shock transfected into JM109 competent bacteria
(Promega, Southampton, UK) and cloned on selective
ampicillin/X-gal LB agar plates. Clones were amplified
with PCR using M13 primers. Sequencing was performed
using BigDye (Applied Biosystems) according to the
manufacturer’s protocol with an ABI 3130XL sequencer.
3. Results
Family B (India) does not share the UK haplotype.
Sequencing results of SNP markers was incompatible
with the shared haplotype of the previously reported UK
families (Fig. 1a). Upstream from the mutation in the
119th FN3 domain were two heterozygous variants,
c.90374C>T (listed as rs191484894 in dbSNP), and a
novel synonymous variant, c.90225C>T (using
NM_001256850 as the reference sequence). Sequencing of
clones of the PCR fragment demonstrated that both
variants are on the same allele as the p.C30071R
mutation at c.90211T>C (Fig. 1b).
Sequencing results from the proband of Family C (Spain)
was compatiblewith the shared haplotype of theUK families
of a minimum size of 673 kbp (defined by rs6433724,
rs6706354, rs6706483, rs919177, the mutation at position
chr2.179410829A>G (reference sequence GRCh37), and
rs35813871) (Fig. 1a). Within this shared region is the
171 kbp haplotype which is shared between all previously
reported UK families with the p.C30071R mutation.
4. Discussion
This study provides definitive proof of the pathogenicity
of the p.C30071R mutation associated with HMERF. To
date, haplotype studies suggest that all patients with this
mutation originated from a very remote common founder
[3,8]. Therefore, in the absence of functional evidence of
pathogenicity for this single amino acid substitution, it
would only be accurate to state that the haplotype
containing the p.C30071R mutation is associated with
HMERF. However, Family B from India has a different
genetic background, with two polymorphisms within the
same FN3 domain that are not present in the UK
patients, and which we show to be in cis with the
p.C30071R mutation. This indicates that the p.C30071R
mutation itself causes HMERF.
HMERF is already considered to be an
under-recognised condition that is more common than
expected and is distributed internationally [3,4,8]. Its true
prevalence is unknown, although the presence of the
p.C30071R mutation on a different haplotype in Family
B indicates the possibility that this position in TTN may
be a mutational hotspot and supports a higher than
expected prevalence, and perhaps a worldwide
distribution of this condition [4,10].
The shared haplotype of Spanish Family C with the UK
families is consistent with our findings suggesting the
p.C30071R mutation was an ancient occurrence, and it is
possible that the other European and Scandinavian
patients share the same common founder. The fact that
this is a late-onset disease thus evading reproductive
selection is probably what allowed the ancestral allele to
have broadly permeated an international population. We
therefore reiterate that titinopathy is an important
diagnostic consideration in patients with autosomal
dominant adult-onset myopathy.
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